Assessing the validity and interpretability of the Simplified Psoriasis Index in Tunisian patients


Ines Chabchoub
Noureddine Litaiem
Soumaya Gara
Kahena Jaber
Mohamed Abderraouf Dhaoui
Faten Zeglaoui


Introduction: Multiple scores have been developed to assess the severity of psoriasis, but these scores have many limitations. The Simplified Psoriasis Index (SPI) is a summary score with separate components for current severity (SPI-s), psychosocial impact (SPI-p), and past history and interventions (SPI-i). It is available in two similar versions: proSPI and saSPI.

Aim: To assess the validity of the SPI by studying its correlation to the benchmark scores in Tunisian patients.

Methods: It was a prospective bicentric study including 80 patients with plaque psoriasis.

Results: The median PASI was 7.6 and the median DLQI was 9. The median proSPI-s was 6 and the median saSPI-s was 8. The median SPI-p was 7. The median SPI-i was 2. There was a strong correlation between the proSPI-s and PASI (r=0.87) and between the proSPI-s and saSPI-s (r=0.82). There was a medium correlation between saSPI-s and PASI (r=0.70) and between SPI-p and DLQI (r=0.67). The threshold value for proSPI-s and saSPI-s was 7.25. The threshold value for SPI-p was 6.5.

Conclusion: The SPI aims to provide a concise but global measure of the severity and impact of psoriasis on quality of life. The use of SPI has several advantages: the simplicity of use, the additional weight given to critical locations of psoriasis, the possibility for the patient to self-assess his own disease, and the possibility of evaluating all the dimensions of psoriasis at the same time.



  1. Richard MA, Aractingi S, Joly P, et al. French adaptation of a new score for global assessment of psoriasis severity: The Simplified Psoriasis Index (SPI). Ann Dermatol Venereol 2019;146(12 Suppl):783–92.
  2. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3 Suppl):210-6.
  3. Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies. Clin Dermatol 2010;28:67-72
  4. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012;148(1 Suppl):95–102.
  5. Chularojanamontri L, Griffiths CEM, Chalmers RJG. The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. J Invest Dermatol 2013;133:1956-62.
  6. Chalmers RJ. Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. Dermatol Clin 2015;33:57–71.
  7. Van Geel MJ, Otero ME, De Jong EM, Van De Kerkhof PC, Seyger MM. Validation of the Simplified Psoriasis Index in Dutch children and adolescents with plaque psoriasis. Br J Dermatol 2017;176(3 Suppl):771–6.
  8. Morais MR, Martins GA, Romiti R, Tonoli RE, Carvalho AVE. Translation and validation of the Simplified Psoriasis Index (SPI) into Brazilian Portuguese. An Bras Dermatol 2018;93:813–8.
  9. Soliman M. Patient-Reported Disease Severity and Quality of Life Among Arabic Psoriatic Patients: A Cross-Sectional Survey. Clin Cosmet Investig Dermatol 2020;13:601-9.
  10. Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol 2010;10:22.
  11. European Medicines Agency. (2004) Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis WWW document. Available from: http://www. guideline/2009/09/WC500003329.pdf.
  12. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005;152(5 Suppl):861–7.
  13. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 2010;130(4 Suppl):933–43.
  14. Chalmers RJ. Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. Dermatol Clin 2015;33:57–71.
  15. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991;124:565–70.
  16. Chularojanamontri L, Griffiths CEM, Chalmers RJG. Responsiveness to change and interpretability of the simplified psoriasis index. J Invest Dermatol 2014;134(2 Suppl):351-8
  17. Meah N, Alsharqi A, Azurdia RM, Owens LC, Parslew R, Chularojanamontri L. Assessing the validity and response distribution of the simplified psoriasis index in patients receiving phototherapy. Australas J Dermatol 2018;59:41-7.